Breaking News Instant updates and real-time market news.

MDXG

MiMedx

$8.87

0.1 (1.14%)

08:40
10/06/16
10/06
08:40
10/06/16
08:40

MiMedx to present seven abstracts on EpiFix and AmnioFix at SAWC meeting

MiMedx announced that seven poster abstracts showing the clinical and cost effective healing results of the company's EpiFix and AmnioFix dehydrated Human Amnion/Chorion Membrane allografts will be presented at the 2016 Symposium on Advanced Wound Care Fall between October 7 and October 9. The seven poster abstracts will report on the clinical and cost effectiveness of EpiFix and AmnioFix dHACM allografts in the healing of diabetic foot ulcers, chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, complex wounds, and hard-to-treat wounds.

  • 09

    Nov

  • 10

    Nov

MDXG MiMedx
$8.87

0.1 (1.14%)

05/17/16
PIPR
05/17/16
NO CHANGE
Target $12
PIPR
Overweight
Osiris false claims lawsuit another overhang, says Piper Jaffray
After MiMedx (MDXG) announced that it has filed suit against Osiris (OSIR), asserting that Osiris "knowingly and willfully made false and misleading representations," Piper Jaffray analyst Edward Tenthoff said it is unclear at this time what merit the claims have, but added that the lawsuit represents "yet another" overhang for Osiris shares. Noting that he expects BioSurgery sales to return Osiris to profitability, Tenthoff maintains an Overweight rating and $12 price target on the stock.
06/29/16
BMUR
06/29/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx expects second half acceleration, says Brean Capital
Brean Capital said MiMedx continues to be confident in Q2 but expects a second half acceleration with surgical uptake the key opportunity. The firm's doctor checks suggest growing interest in using amniotic tissue for tendon repair procedures along with GI surgeons showing interest as well. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.
07/27/16
BMUR
07/27/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx shares remain undervalued, says Brean Capital
Brean Capital believes Mimedx shares remain undervalued following Q2 earnings. The firm said higher spending cutting into its earnings was a disappointment but at this stage in the company's development they noted the focus is on top-line growth, which remains healthy. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.
08/31/16
BMUR
08/31/16
NO CHANGE
Target $12
BMUR
Buy
MiMedx Epifix trial news removes major overhang, says Brean Capital
Brean Capital analyst Jason Wittes said the surprise announcement that MiMedx is close to completing DFU and VLU trials for Epifix ahead of the September FDA hearing to discuss the regulator's guidance on human cells, tissues, and cellular and tissue based products removes a major overhang for the stock. The analyst felt most investors assumed the company was not positioned to immediately address the potential for increased regulatory requirements given their strong stance against up-regulation. Wittes reiterated his Buy rating and $12 price target on MiMedx shares.

TODAY'S FREE FLY STORIES

ENG

ENGlobal

$1.19

0.1 (9.17%)

06:21
06/26/17
06/26
06:21
06/26/17
06:21
Hot Stocks
ENGlobal announces strategic alliance with Coggins International »

ENGlobal Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$32.76

0.46 (1.42%)

06:18
06/26/17
06/26
06:18
06/26/17
06:18
Hot Stocks
Genentech: Emicizumab showed reduction in bleeds across two pivotal studies »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Jul

  • 30

    Jul

GM

General Motors

$34.20

0.01 (0.03%)

06:17
06/26/17
06/26
06:17
06/26/17
06:17
Periodicals
General Motors settles hundreds of ignition switch lawsuits, Reuters reports »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ILMN

Illumina

$185.28

2.29 (1.25%)

06:16
06/26/17
06/26
06:16
06/26/17
06:16
Hot Stocks
Genomics England adopts Illumina's BaseSpace variant interpreter for cancer »

Illumina and Genomics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.88

-0.04 (-0.15%)

06:15
06/26/17
06/26
06:15
06/26/17
06:15
Hot Stocks
Taked, Biological E. Limited to develop low-cost combination vaccines »

Takeda Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

, VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

06:14
06/26/17
06/26
06:14
06/26/17
06:14
Periodicals
Harley-Davidson 'seriously considering bid' for Volkswagen's Ducati, WSJ says »

Harley-Davidson (HOG) is…

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

AUDVF

Audi AG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Oct

MMSI

Merit Medical

$37.80

0.7 (1.89%)

06:13
06/26/17
06/26
06:13
06/26/17
06:13
Recommendations
Merit Medical analyst commentary  »

Piper continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

SSNLF

Samsung

, QCOM

Qualcomm

$56.91

0.44 (0.78%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Periodicals
Samsung to launch Galaxy Note8 in late September, VentureBeat says »

Samsung (SSNLF) is…

SSNLF

Samsung

QCOM

Qualcomm

$56.91

0.44 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ALNY

Alnylam

$85.21

1.25 (1.49%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Hot Stocks
Alnylam: Givosian demonstrated decreased annual attack rate in study »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

CS

Credit Suisse

$13.74

-0.07 (-0.51%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Initiation
Credit Suisse initiated  »

Credit Suisse resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

IBM

IBM

$154.11

-0.29 (-0.19%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Hot Stocks
IBM, AEON to build blockchain-based financial platform for Asian market »

AEON Financial Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

UBS

UBS

$16.06

-0.08 (-0.50%)

06:08
06/26/17
06/26
06:08
06/26/17
06:08
Upgrade
UBS rating change  »

UBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MTNB

Matinas BioPharma

$2.77

0.25 (9.92%)

06:07
06/26/17
06/26
06:07
06/26/17
06:07
Hot Stocks
Matinas: Clinical, mycological responses for MAT2203 didn't meet expectations »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$8.28

0.48 (6.15%)

06:06
06/26/17
06/26
06:06
06/26/17
06:06
Periodicals
Pandora CEO Westergren planning to step down, Recode reports »

Tim Westergren, the CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BBY

Best Buy

$55.18

-0.04 (-0.07%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

06:04
06/26/17
06/26
06:04
06/26/17
06:04
Recommendations
Best Buy, Amazon.com analyst commentary  »

Piper views Best Buy as…

BBY

Best Buy

$55.18

-0.04 (-0.07%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Aug

LOW

Lowe's

$76.07

-2.27 (-2.90%)

06:02
06/26/17
06/26
06:02
06/26/17
06:02
Hot Stocks
Lowe's completes $512M acquisition of Maintenance Supply Headquarters »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMID

American Midstream Partners

$11.95

0.25 (2.14%)

06:01
06/26/17
06/26
06:01
06/26/17
06:01
Hot Stocks
American Midstream Partners announces binding open season for Bakken System »

American Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACTG

Acacia Research

$4.10

0.05 (1.23%)

06:00
06/26/17
06/26
06:00
06/26/17
06:00
Hot Stocks
Acacia Research enters into patent license agreement with ZTE Corporation »

Acacia Research announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:00
06/26/17
06/26
06:00
06/26/17
06:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.74

0.38 (1.70%)

05:58
06/26/17
06/26
05:58
06/26/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$119.43

0.51 (0.43%)

05:58
06/26/17
06/26
05:58
06/26/17
05:58
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$33.60

1.82 (5.73%)

05:57
06/26/17
06/26
05:57
06/26/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$20.00

1.02 (5.37%)

05:57
06/26/17
06/26
05:57
06/26/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$28.47

-1.53 (-5.10%)

05:56
06/26/17
06/26
05:56
06/26/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.00

-3.27 (-5.17%)

05:56
06/26/17
06/26
05:56
06/26/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.